In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novation's Debut

Executive Summary

The new merged supply chain programs of VHA and University Hospital Consortium is off the ground, headed by a former Baxter executive. The question for suppliers is the approach the organization will take--confrontational or conciliatory--as it shapes a dedicated program.

You may also be interested in...



Novation's Play in Physician-Preferred Products

The Senate hearings held last year on hospital group purchasing highlighted one of the most difficult challenges hospital groups face: getting physician-preferred products like drug-eluting stents and orthopedic implants under contract. For the past ten years, Novation has had a program focused specifically on such high tech devices, and though it hasn't always been easy, the program has been remarkably successful in getting manufacturers to put products on contract.

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV000806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel